VEGF inhibitors in glaucoma surgery

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Vascular endothelial growth factor (VEGF) is a signaling protein, that controls vasculogenesis, angiogenesis, vascular support and stimulates permeability of small blood vessels. The following isoforms are presently known: VEGF-A, VEGF-B, VEGF-C, VEGF-В and PGF. VEGF-A, that regulates neoangiogenesis and fibroblast formation, is thought to play the most important role in human organism. Increased expression of VEGF may lead to development and aggravation of pathological conditions including oncology. The article presents a review of preclinical and clinical studies of the main VEGF-inhibitors - bevacizumab and ranibizumab, as well as a brief account on other existing medications of this group. It describes ophthalmological indications for the use of antiangiogenetic agents, as well as the ways of their possible off-label use. The review presents investigations of intravitreal and intracameral injections of VEGF-inhibitors in patients with retinal, chorioidal, iris, and anterior chamber angle neovascularization. It gives examples of successful anti-VEGF use before Ahmed glaucoma valve drainage device implantation and in cases of neovascular glaucoma, induced by radiation therapy for intraocular tumors. Tenon’s capsule’s fibroblasts take part in the process of postoperative wound healing and scarring. According to the latest research, this process could be modulated by angiogenesis inhibitors. This review also recounts the use of anti-angiogenic agents to inhibit postoperative fibroblast proliferation, when used as monotherapy, or as an adjuvant to mitomycin С or 5-fluorouracil. It reviews the research on VEGF-inibitors use in combination with postoperative needling.

Full Text

Restricted Access

About the authors

Vardan R Mamikonyan

Research Institute of Eye Diseases

Email: info@eyeacademy.ru
professor, D.Med.Sc., deputy director

Sergej Y Petrov

Research Institute of Eye Diseases

Email: post@glaucomajournal.ru
Ph.D., senior research associate of the Glaucoma Department

Daria M Safonova

Research Institute of Eye Diseases

Email: dmsafonova@gmail.com
M.D., post-graduate student

References

  1. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(23):10457-10461. doi: 10.1073/pnas.92.23.10457.
  2. Andre´ T, Chibaudel B. Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer. Bulletin du cancer. 2013;100(10): 1023-1025.
  3. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26(3):352-354. doi: 10.1097/00006982-200603000-00016.
  4. Beir῀ao NM, Miranda V, Beir῀ao I, et al. The use of intravitreal ranibizumab to treat neovascular glaucoma because of retinal amyloid angiopathy in familial amyloidosis transthyretin v30m related. Retinal cases & brief reports. 2013;7(1):114-116. doi: 10.1097/icb.0b013e3182681259
  5. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67(8):1199-1199. doi: 10.2165/00003495-200767080-00007.
  6. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007; 67(8):1199-1206. do: 10.2165/00003495-200767080-00010.
  7. Caujolle JP, Maschi C, Freton A, et al. Treatment of Neovascular Glaucoma after Proton Therapy for Uveal Melanomas with Ranibizumab Injection: Preliminary Results. Ophthalmic Research. 2012;47(2):57-60. doi: 10.1159/000328633.
  8. Chalam KV, Gupta SK, Grover S, et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. European J of Ophthalmology. 2008;18(2):255-262.
  9. Choi JY, Choi J, Kim Y-D. Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series. Korean j of ophthalmology. 2010;24(1):47-52. doi: 10.3341/kjo.2010.24.1.47.
  10. Chua BE, Nguyen DQ, Qin Q, et al. Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study. Clinical & Experimental Ophthalmology. 2012;40(8):773-779. doi: 10.1111/j.1442-9071.2012.02798.x
  11. Coote MA, Ruddle JB, Qin Q, Crowston JG. Vascular changes after intra-bleb injection of bevacizumab. J of glaucoma. 2008; 17(7):517-518. doi: 10.1097/ijg.0b013e31815f5345.
  12. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354-356. doi: 10.1097/00006982-200603000-00017.
  13. Desai RU, Singh K, Lin SC. Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open-angle glaucoma: a pilot study. Clinical & experimental ophthalmology. 2012;41(2):155-158. doi: 10.1111/j.1442-9071.2012.02836.x.
  14. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am j of physiology - Cell physiology. 2001;280(6).
  15. Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U. Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clinical & experimental ophthalmology. 2007;35(9):878-880. doi: 10.1111/j.1442-9071.2007.01632.x.
  16. Elmekawey H, Khafagy A. Intracameral Ranibizumab and Subsequent Mitomycin C Augmented Trabeculectomy in Neovascular Glaucoma. J of glaucoma. 2013;23(7):437-440. doi: 10.1097/ijg.0b013e3182946398
  17. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews. 2004;25(4):581-611. doi: 10.1210/er.2003-0027.
  18. Ferrara N, Davis-Smyth T. The Biology of Vascular Endothelial Growth Factor. Endocrine Reviews. 1997;18(1):4-25. doi: 10.1210/er.18.1.4.
  19. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery. 2004;3(5):391-400. doi: 10.1038/nrd1381.
  20. Folkman J. Angiogenesis. An Rev Med. 2006;57(1):1-18. doi: 10.1146/annurev.med.57.121304.131306.
  21. Folkman J. Incipient angiogenesis. J of the National Cancer Institute. 2000;92(2):94-95. doi: 10.1093/jnci/92.2.94.
  22. Folkman J. What is the evidence that tumors are angiogenesis dependent? J of the National Cancer Institute. 1990;82(1):4-6. doi: 10.1093/jnci/82.1.4.
  23. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature. 1980; 288(5791):551-556. doi: 10.1038/288551a0.
  24. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. The J of experimental medicine. 1971;133(2):275-288. doi: 10.1084/jem.133.2.275.
  25. Genentech I. AVASTIN® (bevacizumab). Cell. 2009;44:1-25.
  26. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23(5):487-491. doi: 10.1089/jop.2007.0036.
  27. Grewal DS, Jain R, Kumar H, Grewal SPS. Evaluation of Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy. A Pilot Study. Ophthalmology. 2008;115(12):2141-2145. doi: 10.1016/j.ophtha.2008.06.009.
  28. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J of ophthalmology. 2006;142(1):158-160. doi: 10.1016/j.ajo.2006.02.045.
  29. Grogan K. Sanofi posts good news, bad news for cancer drug Zaltrap. 2012.
  30. Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. The British J of ophthalmology. 2009;93(2):273-274. doi: 10.1136/bjo.2008.145714.
  31. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Survey of Ophthalmology. 2009;54(3):372-400. doi: 10.1016/j.survophthal.2009.02.004.
  32. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J of clin oncology: official journal of the American Society of Clinical Oncology. 2004;23(5):1011-1027. doi: 10.1200/jco.2005.06.081.
  33. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacological reviews. 2004; 56(4):549-580. doi: 10.1124/pr.56.4.3.
  34. How A, Chua JLL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Investigative ophthalmology & visual science. 2010;51(2):928-932. doi: 10.1167/iovs.09-3949.
  35. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142(6):1054-1056. doi: 10.1016/j.ajo.2006.06.066.
  36. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. The J of experimental medicine. 2003;198(3):483-489. doi: 10.1084/jem. 20022027.
  37. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007; 39(2): 121-122. doi: 10.1159/000099248.
  38. Jurkowska-Dudzin´ska J, Kosior-Jarecka E, Zarnowski T. Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clinical & Experimental Ophthalmology. 2012; 40(4): e135-142. doi: 10.1111/j.1442-9071.2011.02608.x.
  39. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: A pilot study. Am J of Ophthalmology. 2010;150(3):399-403.e391. doi: 10.1016/j.ajo.2010.03.025.
  40. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37(2):144-146.
  41. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37(2):148-150.
  42. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727-739. doi: 10.1038/nrc905.
  43. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-844. doi: 10.1038/362841a0.
  44. Kitnarong N, Sriyakul C, Chinwattanakul S. A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma. Ophthalmology and Therapy. 2015;4(1):33-41. doi: 10.1007/s40123-015- 0033-3.
  45. Klos-Rola J, Tulidowicz-Bielak M, Zarnowski T. Effects of topical bevacizumab application on early bleb failure after trabeculectomy: observational case series. Clinical ophthalmology. 2013;(7): 1929-1935. doi: 10.2147/opth.s45210.
  46. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of ophthalmology. 2002;120(3):338-346. doi: 10.1001/archopht.120.3.338.
  47. Li Z, van Bergen T, van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol and Vis Sci. 2009;50(11):5217-5225. doi: 10.1167/iovs.08-2662.
  48. Lu¨ke J., Nassar K., Lu¨ke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma results from a prospective interventional case series. Graefe’s archive for clinical and experimental Ophthalmology = Albrecht von Graefes Archiv fu¨r Klinische und Experimentelle Ophthalmologie. 2013; 251(10):2403-2413. doi: 10.1007/s00417-013-2428-y.
  49. Makri OE, Psachoulia C, Exarchou A, Georgakopoulos CD. Intravitreal Ranibizumab as Palliative Therapy for Iris Metastasis Complicated With Refractory Secondary Glaucoma. J of Glaucoma. 2016;25(1):e53-e55. doi: 10.1097/ijg.0000000000000163.
  50. Memarzadeh F, Varma R, Lin L-T, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest ophthalmol & vis sci. 2009; 50(7):3233-3237. doi: 10.1167/iovs.08-2441.
  51. Mukherji SK. Bevacizumab (Avastin). AJNR American journal of neuroradiology. 2009;31(2):235-236. doi: 10.3174/ajnr.a1987.
  52. Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulmonary pharmacology & therapeutics. 2006;19(1):61-69.
  53. News. Zaltrap approved for metastatic colorectal cancer. Cancer Discovery. 2012;2(10):OF8-OF8. doi: 10.1158/2159-8290.cd-nb2012-095.
  54. Newswire PR. Lilly Provides Update on Strategy and Announces 2015 Financial Guidance. 2015.
  55. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123-132. doi: 10.1038/nrd1955.
  56. Ng EWM, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann of the Acad of Sci. 2006;1082(1):151-171. doi: 10.1196/annals.1348.062.
  57. Nieves BJ, D’Amore PA, Bryan BA. The function of vascular endothelial growth factor. BioFactors. 2009;35(4):332-337. doi: 10.1002/biof.46.
  58. Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J of Ophthalmol. 2012;153(2):352-357.e351. doi.: 10.1016/j.ajo.2011.08.005.
  59. O’Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon’s fibroblasts in vitro. Invest ophthalmol and vis sci. 2010;51(12):6524-6532. doi: 10.1167/iovs.10-5669.
  60. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am j of ophthalmol. 2006;142(1):155-158. doi: 10.1016/j.ajo.2006.02.015.
  61. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. The Am J of pathology. 2000;156(2):697-707. doi: 10.1016/s0002-9440(10)64773-6.
  62. Purcell JM, Teng CC, Tello C, et al. Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy. Invest Ophthalmol & Vis Sci. 2008;49(13):4165-4165.
  63. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J of Cell Sci. 1995;108 (Pt 6):2369-2379.
  64. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc of the Nat Acad of Sci USA. 1996;93(10):4851-4856. doi: 10.1073/pnas.93.10.4851.
  65. Sasamoto Y, Oshima Y, Miki A, et al. Clinical Outcomes and Changes in Aqueous Vascular Endothelial Growth Factor Levels After Intravitreal Bevacizumab for Iris Neovascularization and Neovascular Glaucoma: A Retrospective Two-Dose Comparative Study. JOPT. 2012;28(1):41-48. doi: 10.1089/jop.2011.0059.
  66. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (N.Y.). 1983;219(4587):983-985. doi: 10.1126/science.6823562.
  67. Simsek T, Cankaya AB, Elgin U. Comparison of Needle Revision with Subconjunctival Bevacizumab and 5-Fluorouracil Injection of Failed Trabeculectomy Blebs. JOPT. 2012; 28(5): 542-546. doi: 10.1089/jop.2012.0035.
  68. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Archives of Ophthalmology. 1996;114(8):964-970. doi: 10.1001/archopht.1996.01100140172010.
  69. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol & Vis Sci. 2004;45(2):368-374. doi: 0.1167/iovs.03-0106.
  70. Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Experimental Eye Research. 2011;93(5):689-699. doi: 10.1016/j.exer.2011.08.016.
  71. Vandewalle E, Abeg῀ao Pinto L, Van Bergen T, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. The Br J of Ophthalmol. 2013; 98(1):73-78. doi: 10.1136/bjophthalmol-2013-303966.
  72. Vasudevan SK. Anti-VEGF Anti-Fibrosis - A Comparison of Ranibizumab and Bevacizumab in vitro. Invest Ophthalmol & Vis Sci. 2009;50(13):466-466.
  73. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-1580, 1580.e1571-1573. doi: 10.1016/j.ophtha.2008.02.026.
  74. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58(4):439-451. doi: 10.1006/exer.1994.1037.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Mamikonyan V.R., Petrov S.Y., Safonova D.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies